Literature DB >> 12197886

Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Abeta peptide.

A H Tammer1, G Coia, R Cappai, S Fuller, C L Masters, P Hudson, J R Underwood.   

Abstract

A recombinant Fab antibody, designated 1E8-4b, which reacts with the Alzheimer's disease (AD)-related Abeta peptides, Abeta[1-40], Abeta[1-42] and Abeta[1-43] has been developed. The 1E8-4b Fab was constructed by cloning the V(H)C(H1) and V(L)C(L) domains from the parent hybridoma 1E8 antibody, reported previously to recognize these Abeta peptides. Briefly, a C-terminal Flag tag sequence was incorporated into this construct, which was ligated into the vector pHFA2 and expressed in Escherichia coli. Following purification on an M2 anti-Flag affinity column, the 1E8-4b recombinant Fab antibody was shown to bind plaques within sections of brain tissue from CERAD-defined AD patients by immunohistochemistry. ELISA, epitope mapping and immunoblotting confirmed the recognition of the Abeta1-40/42/43] peptides by the 1E8-4b Fab. The 1E8-4b Fab did not recognize APP695 or APP770 which contain the Abeta sequence. The Abeta specificity of the recombinant 1E8-4b Fab antibody was identical to the parent 1E8 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197886      PMCID: PMC1906481          DOI: 10.1046/j.1365-2249.2002.01905.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

Review 1.  Amyloid and lipids in the pathology of Alzheimer disease.

Authors:  A E Roher; Y M Kuo; K M Kokjohn; M R Emmerling; S Gracon
Journal:  Amyloid       Date:  1999-06       Impact factor: 7.141

Review 2.  Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches.

Authors:  C Soto
Journal:  J Mol Med (Berl)       Date:  1999-05       Impact factor: 4.599

Review 3.  Oestrogens and Alzheimer's disease.

Authors:  M H Birkhäuser; J Strnad; C Kämpf; M Bahro
Journal:  Int J Geriatr Psychiatry       Date:  2000-07       Impact factor: 3.485

Review 4.  Alzheimer's disease: the advent of effective therapy.

Authors:  J Hecker
Journal:  Aust N Z J Med       Date:  1998-12

5.  Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene.

Authors:  M J Smith; R J Gardner; M A Knight; S M Forrest; K Beyreuther; E Storey; C A McLean; R G Cotton; R Cappal; C L Masters
Journal:  Neuroreport       Date:  1999-02-25       Impact factor: 1.837

6.  The effect of epitope density and antibody affinity on the ELISA as analysed by monoclonal antibodies.

Authors:  A M Lew
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

7.  The kinetics of antibody binding to membrane antigens in solution and at the cell surface.

Authors:  D W Mason; A F Williams
Journal:  Biochem J       Date:  1980-04-01       Impact factor: 3.857

8.  Influence of antibody affinity on the performance of different antibody assays.

Authors:  G R Nimmo; A M Lew; C M Stanley; M W Steward
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

9.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

10.  Identification of structural variations in the carboxyl terminus of Alzheimer's disease-associated beta A4[1-42] amyloid using a monoclonal antibody.

Authors:  U L Jayasena; S K Gribble; A McKenzie; K Beyreuther; C L Masters; J R Underwood
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

View more
  6 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

2.  Vitamin D2-enriched button mushroom (Agaricus bisporus) improves memory in both wild type and APPswe/PS1dE9 transgenic mice.

Authors:  Louise Bennett; Cindy Kersaitis; Stuart Lance Macaulay; Gerald Münch; Garry Niedermayer; Julie Nigro; Matthew Payne; Paul Sheean; Pascal Vallotton; Dimitrios Zabaras; Michael Bird
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 3.  Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer's Disease.

Authors:  Zhi-Ting Sun; Chi Ma; Guang-Jian Li; Xiang-Yu Zheng; Yi-Tong Hao; Yu Yang; Xu Wang
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

4.  Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.

Authors:  Mirko Bibl; Marion Gallus; Volker Welge; Hermann Esselmann; Stefanie Wolf; Eckart Rüther; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2012-04-19       Impact factor: 3.575

5.  Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Authors:  Xavier Hadoux; Flora Hui; Jeremiah K H Lim; Colin L Masters; Alice Pébay; Sophie Chevalier; Jason Ha; Samantha Loi; Christopher J Fowler; Christopher Rowe; Victor L Villemagne; Edward N Taylor; Christopher Fluke; Jean-Paul Soucy; Frédéric Lesage; Jean-Philippe Sylvestre; Pedro Rosa-Neto; Sulantha Mathotaarachchi; Serge Gauthier; Ziad S Nasreddine; Jean Daniel Arbour; Marc-André Rhéaume; Sylvain Beaulieu; Mohamed Dirani; Christine T O Nguyen; Bang V Bui; Robert Williamson; Jonathan G Crowston; Peter van Wijngaarden
Journal:  Nat Commun       Date:  2019-09-17       Impact factor: 14.919

Review 6.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.